These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. Clinical characteristics and immunogenetics of BCGosis/BCGitis in Chinese children: a 6 year follow-up study. Ying W; Sun J; Liu D; Hui X; Yu Y; Wang J; Wang X PLoS One; 2014; 9(4):e94485. PubMed ID: 24722620 [TBL] [Abstract][Full Text] [Related]
43. Intradermal BCG vaccination complications--analysis of 51 cases. de Souza GR; Sant'Anna CC; Lapa e Silva JR; Mano DB; Bethlem NM Tubercle; 1983 Mar; 64(1):23-7. PubMed ID: 6845431 [TBL] [Abstract][Full Text] [Related]
45. First experience with BCG discontinuation in Europe. BCG vaccination and HIV infection. ten Dam HG Bull Int Union Tuberc Lung Dis; 1990; 65(2-3):38-9. PubMed ID: 2257354 [No Abstract] [Full Text] [Related]
46. [HIV-infection, AIDS and BCG vaccination]. Toida I Kekkaku; 1993 Jun; 68(6):435-44. PubMed ID: 8341039 [TBL] [Abstract][Full Text] [Related]
47. A novel evaluation of genetic polymorphism in BCG adenitis. Hassanzad M; Farnia P; Darougar S; Velayati AA Turk J Pediatr; 2019; 61(3):466-470. PubMed ID: 31916732 [TBL] [Abstract][Full Text] [Related]
48. Safety of BCG Vaccination in Pediatric Liver Transplant Recipients. Kinoshita N; Shoji K; Funaki T; Fukuda A; Sakamoto S; Kasahara M; Miyairi I Transplantation; 2018 Apr; 102(4):e125. PubMed ID: 29346255 [No Abstract] [Full Text] [Related]
49. New studies of BCG: implications for tuberculosis vaccines. von Reyn CF Lancet Infect Dis; 2012 Apr; 12(4):259-60. PubMed ID: 22071251 [No Abstract] [Full Text] [Related]
53. BCG vaccination confers poor protection against M. tuberculosis HN878-induced central nervous system disease. Tsenova L; Harbacheuski R; Sung N; Ellison E; Fallows D; Kaplan G Vaccine; 2007 Jul; 25(28):5126-32. PubMed ID: 17241704 [TBL] [Abstract][Full Text] [Related]
54. The rate of adverse events following BCG vaccination in Poland. Krysztopa-Grzybowska K; Paradowska-Stankiewicz I; Lutyńska A Przegl Epidemiol; 2012; 66(3):465-9. PubMed ID: 23230718 [TBL] [Abstract][Full Text] [Related]
55. The benefits and risks of bacille Calmette-Guérin vaccination among infants at high risk for both tuberculosis and severe combined immunodeficiency: assessment by Markov model. Clark M; Cameron DW BMC Pediatr; 2006 Mar; 6():5. PubMed ID: 16515694 [TBL] [Abstract][Full Text] [Related]
56. Current status of new tuberculosis vaccine in children. Pang Y; Zhao A; Cohen C; Kang W; Lu J; Wang G; Zhao Y; Zheng S Hum Vaccin Immunother; 2016 Apr; 12(4):960-70. PubMed ID: 27002369 [TBL] [Abstract][Full Text] [Related]
57. [Osteomyelitis as a complication following BCG vaccination]. Withagen MI; Ruitenberg A; van Soolingen D; Rümke HC; Diepstraten AF; de Groot R Ned Tijdschr Geneeskd; 1995 Oct; 139(40):2047-50. PubMed ID: 7477555 [TBL] [Abstract][Full Text] [Related]
58. The risk of disseminated Bacille Calmette-Guerin (BCG) disease in HIV-infected children. Hesseling AC; Marais BJ; Gie RP; Schaaf HS; Fine PE; Godfrey-Faussett P; Beyers N Vaccine; 2007 Jan; 25(1):14-8. PubMed ID: 16959383 [TBL] [Abstract][Full Text] [Related]
59. Alternative BCG delivery strategies improve protection against Mycobacterium tuberculosis in non-human primates: Protection associated with mycobacterial antigen-specific CD4 effector memory T-cell populations. Sharpe S; White A; Sarfas C; Sibley L; Gleeson F; McIntyre A; Basaraba R; Clark S; Hall G; Rayner E; Williams A; Marsh PD; Dennis M Tuberculosis (Edinb); 2016 Dec; 101():174-190. PubMed ID: 27865390 [TBL] [Abstract][Full Text] [Related]
60. Mycobacterium tuberculosis virulence: insights and impact on vaccine development. Delogu G; Provvedi R; Sali M; Manganelli R Future Microbiol; 2015; 10(7):1177-94. PubMed ID: 26119086 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]